205 related articles for article (PubMed ID: 25201050)
21. Immunohistochemical characterisation of molecular subtypes in endometrial cancer.
Łapińska-Szumczyk SM; Supernat AM; Majewska HI; Gulczyński J; Biernat W; Wydra D; Żaczek AJ
Int J Clin Exp Med; 2015; 8(11):21981-90. PubMed ID: 26885170
[TBL] [Abstract][Full Text] [Related]
22. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
23. [Correlation between estrogen receptor status and clinicopathologic parameters in endometrial cancer: a comparative study by immunohistochemistry using different scoring systems].
Wang Y; Ma XL; Xi CG; Lin J; Ren CX; Liu CR
Zhonghua Bing Li Xue Za Zhi; 2013 Aug; 42(8):509-14. PubMed ID: 24246914
[TBL] [Abstract][Full Text] [Related]
24. Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study.
Srijaipracharoen S; Tangjitgamol S; Tanvanich S; Manusirivithaya S; Khunnarong J; Thavaramara T; Leelahakorn S; Pataradool K
Asian Pac J Cancer Prev; 2010; 11(1):215-20. PubMed ID: 20593959
[TBL] [Abstract][Full Text] [Related]
25. The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.
Ye JH; Yu J; Huang MY; Mo YM
Breast Cancer; 2024 May; 31(3):417-425. PubMed ID: 38561479
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR-/HER2+ breast cancer subtypes.
Ding W; Ye D; Chen H; Lin Y; Li Z; Tu C
Breast Cancer; 2024 Mar; 31(2):295-304. PubMed ID: 38231460
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
28. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M; Zhao L; Shen D; Li X; Wang J; Wei L
Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
[TBL] [Abstract][Full Text] [Related]
29. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
30. p53 as a marker of prognosis in African-American women with breast cancer.
Dookeran KA; Dignam JJ; Ferrer K; Sekosan M; McCaskill-Stevens W; Gehlert S
Ann Surg Oncol; 2010 May; 17(5):1398-405. PubMed ID: 20049641
[TBL] [Abstract][Full Text] [Related]
31. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
32. The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors.
Panousis D; Patsouris E; Lagoudianakis E; Pappas A; Kyriakidou V; Voulgaris Z; Xepapadakis G; Manouras A; Athanassiadou AM; Athanassiadou P
Eur J Gynaecol Oncol; 2011; 32(2):156-9. PubMed ID: 21614903
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of TOP2A as a Predictive Marker for Endometrial Cancer With Taxane-Containing Adjuvant Chemotherapy.
Ito F; Furukawa N; Nakai T
Int J Gynecol Cancer; 2016 Feb; 26(2):325-30. PubMed ID: 26588239
[TBL] [Abstract][Full Text] [Related]
34. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
35. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
[TBL] [Abstract][Full Text] [Related]
36. Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype.
Mao J; Hu J; Zhang Y; Shen J; Dong F; Zhang X; Ming J; Huang T; Run X
Front Endocrinol (Lausanne); 2021; 12():628939. PubMed ID: 33972826
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study.
Kim EK; Noh WC; Han W; Noh DY
World J Surg; 2011 Jun; 35(6):1244-53. PubMed ID: 21472372
[TBL] [Abstract][Full Text] [Related]
38. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
[TBL] [Abstract][Full Text] [Related]
39. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
